Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality.

[1]  D. Grobbee,et al.  Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. , 2003, European heart journal.

[2]  R. Sakata,et al.  Long-term results of coronary artery bypass grafting in patients with renal insufficiency. , 2003, The Annals of thoracic surgery.

[3]  E. Braunwald,et al.  Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). , 2002, The American journal of cardiology.

[4]  A. Jaffe,et al.  Acute Myocardial Infarction and Renal Dysfunction: A High-Risk Combination , 2002, Annals of Internal Medicine.

[5]  M. Mcclellan,et al.  Association of Renal Insufficiency with Treatment and Outcomes after Myocardial Infarction in Elderly Patients , 2002, Annals of Internal Medicine.

[6]  R. Califf,et al.  Prognostic Implications of Abnormalities in Renal Function in Patients With Acute Coronary Syndromes , 2002, Circulation.

[7]  M. Bell,et al.  The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. , 2002, Journal of the American College of Cardiology.

[8]  H. Hirose,et al.  Coronary artery bypass grafting for patients with non-dialysis-dependent renal dysfunction (serum creatinine > or =2.0 mg/dl). , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[9]  G. O'connor,et al.  Risks of Morbidity and Mortality in Dialysis Patients Undergoing Coronary Artery Bypass Surgery , 2000, Circulation.

[10]  InTIME-II Investigators,et al.  Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. , 2000, European heart journal.

[11]  E. Antman,et al.  Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. , 2000, European heart journal.

[12]  E. Antman,et al.  TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation: An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy , 2000, Circulation.

[13]  C M Gibson,et al.  Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. , 2000, Circulation.

[14]  E. Antman,et al.  Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. , 1999, Circulation.

[15]  E. Braunwald,et al.  Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. , 1999, Circulation.

[16]  Robert J. Anderson,et al.  Clinical Nephrology – Epidemiology – Clinical TrialsRenal failure predisposes patients to adverse outcome after coronary artery bypass surgery , 1999 .

[17]  Thomas E. Moritz,et al.  Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery , 1999 .

[18]  R. Giugliano,et al.  TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. , 1998, Circulation.

[19]  H. White,et al.  Abnormal coronary flow in infarct arteries 1 year after myocardial infarction is predicted at 4 weeks by corrected Thrombolysis in Myocardial Infarction (TIMI) frame count and stenosis severity. , 1998, The American journal of cardiology.

[20]  J. Dodge,et al.  Thrombolysis in Myocardial Infarction frame count in saphenous vein grafts. , 1998, American heart journal.

[21]  M. Borger,et al.  Coronary artery bypass grafting in patients with non-dialysis-dependent renal insufficiency. , 1997, Circulation.

[22]  E. Braunwald,et al.  TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. , 1997, Circulation.

[23]  E. Braunwald,et al.  TIMI frame count: a quantitative method of assessing coronary artery flow. , 1996, Circulation.

[24]  T Sandor,et al.  Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials. , 1992, The American journal of cardiology.

[25]  W. Ganz,et al.  The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[26]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[27]  E. Rubinstein,et al.  Prediction of creatinine clearance from serum creatinine concentration based on lean body mass , 1981, Clinical pharmacology and therapeutics.